Atea Pharmaceuticals, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Atea Pharmaceuticals, Inc. (AVIR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $4.29 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- Atea Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $4.24, a 38.56% increase year-over-year.
- Atea Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.06, a 26.44% decline year-over-year.
- Atea Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $4.16, a 9.37% decline year-over-year.
- Atea Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $4.59.
- Atea Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $3.09, a 24.63% decline from fiscal 2024.
- Atea Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $4.10, a 8.48% decline from fiscal 2023.
- Atea Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $4.48, a 36.72% decline from fiscal 2022.
- Atea Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $7.08, a 87.16% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.29 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $4.24 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $3.09 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $3.09 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $3.09 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $3.06 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | $4.10 10-K · filed 2025-03-06 | |||
| 2024-09-30 | $4.10 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $4.10 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $4.16 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $4.48 10-K · filed 2024-02-28 | |||
| 2023-09-30 | $4.49 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | $4.53 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $4.59 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $7.08 10-K · filed 2023-02-28 | |||
| 2021-12-31 | $55.14 10-K · filed 2022-02-28 | |||
| 2020-12-31 | $14.93 10-K · filed 2021-03-30 | |||
| 2020-09-30 | $6.38 10-Q · filed 2020-12-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |